Kleine-Levin Syndrome (Sleeping Beauty Syndrome)
Clinical Features
Kleine-Levin syndrome is a rare recurrent hypersomnia disorder characterized by distinct episodes lasting one to several weeks, featuring severe hypersomnia (>15 hours/day) combined with cognitive impairment, behavioral changes, and psychiatric symptoms, with complete return to baseline between episodes. 1
Core Diagnostic Criteria
The diagnosis requires three essential elements 1:
- Reliable history of distinct episodes lasting one to several weeks with complete inter-episode recovery
- Severe hypersomnia (sleep >15 hours/day) during episodes
- Associated symptoms including at least one of:
Epidemiology and Demographics
- Prevalence is approximately 1.8 per million in France 2
- Male predominance (64%) 2
- Typical onset during teenage years (80% of cases) 2
- Birth and developmental abnormalities are more frequent (45%) compared to controls 2
Episode Characteristics
Typical episodes present with 3:
- Hypersomnolence in 94.32% of cases
- Cognitive impairment in 67.37%
- Derealization/altered perception in 38.32%
- Severe apathy in 44.63%
- Compulsive eating in 59.58%
- Increased sexual drive in 33.68%
- Odd behaviors in 45.05%
- Psychiatric features in 71.58%
Atypical presentations can occur 3:
- Recurrent insomnia instead of hypersomnia (1.05%)
- Alternation between hypersomnolence and insomnia (4.63%)
- Anorexia instead of compulsive eating (9.05%)
- Decreased sexual drive (1.47%)
Prolonged Episodes (>30 days)
One-third of patients experience prolonged episodes with distinct characteristics 2:
- Longer first episode duration (32 ± 33 vs 11 ± 6 days)
- Longer mean episode duration (23 ± 19 vs 10 ± 3 days)
- Longer disease course (9 ± 6 vs 6 ± 4 years)
- Shorter sleep time during episodes paradoxically
- Higher anxiety levels and increased agitation
- More feelings of disembodiment and amnesia
- Between episodes: more fatigue, need for naps, rapid sleep onset, higher anxiety/depression scores 2
Diagnostic Workup
Essential Evaluations
EEG during episodes 1:
- May show slow rhythms during symptomatic periods
- Critical to rule out epilepsy as a differential diagnosis
Functional brain imaging 1, 4:
- Shows hypoactivity of posterior associative cortex and hippocampus during both symptomatic and asymptomatic periods
- Recent data indicates functional imaging studies are often abnormal both during and between episodes 4
Circadian rhythm assessment 4:
- Amplitude of circadian active/rest cycles significantly decreases during hypersomnia attacks
- During asymptomatic periods, does not differ significantly from controls
Differential Diagnosis
Mental disorders are the most frequent differential diagnoses 2. Among 166 referred patients, the breakdown was 2:
- Typical primary KLS: 120 patients (72%)
- Psychiatric differential diagnoses: 29 patients (17%)
- Secondary KLS (brain diseases): 4 patients
- Atypical syndrome: 7 patients
Genetic Considerations
Recent genetic findings include 4:
- Variation in TRANK1 gene identified in genome-wide association studies
- Rare variations in LMOD3 gene, some likely pathogenic
- Normal karyotypes despite increased developmental abnormalities 2
Treatment Options
Pharmacological Treatment
For acute episode prevention, lithium is the only medication with guideline support. The American Academy of Sleep Medicine suggests clinicians use lithium for treatment of Kleine-Levin syndrome in adults (conditional recommendation). 5
Lithium Therapy
Dosing and monitoring requirements 5:
- Black box warning: Lithium toxicity closely related to serum concentrations and can occur at doses close to therapeutic levels
- Serum lithium determinations must be available before initiating therapy
- Monitor serum concentrations twice per week during acute phase until stabilized
- Regular monitoring of clinical state and serum lithium required throughout treatment
Efficacy and adverse effects 5:
- Demonstrated clinically significant improvement in disease severity in prospective open-label study
- Overall quality of evidence: very low
- Common adverse effects: tremor, polyuria-polydipsia, diarrhea, subclinical hypothyroidism
- No lithium toxicity reported in KLS studies
- No serious adverse events in open-label studies
Contraindications and warnings 5:
- May cause fetal harm based on animal and human studies
- Balance of risks and harms different for pregnant and breastfeeding women
Alternative Preventive Agents
Valproate (off-label, after agreement from reference centers) 1:
- Helps reduce frequency and severity of episodes
- Used in combination with adequate sleep habits
IV methylprednisolone 1:
- Helps reduce long episode duration (>30 days)
- Insufficient evidence for formal guideline recommendation 5
Non-Pharmacological Management
Lifestyle modifications 1:
- Adequate sleep habits maintenance
- Avoidance of alcohol
- Avoidance of infections (precipitating factors more frequent in males at 67.31% vs 49.55% in females) 3
Emerging Experimental Treatments
Intranasal photobiomodulation with methylene blue 6:
- Case report showed remission of KLS episode with no further episodes after treatment
- Requires further validation before clinical recommendation
Clinical Course and Prognosis
KLS attenuates with time when starting during teenage years 1:
- Episodes become less frequent over time
- Episodes become less severe over time
- Mean disease course: 6-9 years depending on episode length 2
Long-term psychiatric risk 4:
- Patients with KLS are at higher risk of developing psychiatric disorders during follow-up
- Requires ongoing psychiatric monitoring even between episodes
Critical Clinical Pitfalls
Do not dismiss as psychiatric illness: Mental disorders are the most common misdiagnosis (17% of referred patients) 2. The key distinguishing feature is the episodic nature with complete return to baseline between episodes.
Monitor for prolonged episodes: One-third of patients develop episodes >30 days requiring more aggressive intervention with IV methylprednisolone 2, 1.
Between-episode symptoms are real: Recent functional imaging and neuropsychological data challenge the notion that KLS is completely benign between episodes 4, 7. Patients with prolonged episodes show persistent fatigue, need for naps, and elevated anxiety/depression scores 2.
Lithium requires intensive monitoring: The narrow therapeutic window demands twice-weekly serum level checks during stabilization 5. Ensure laboratory access before initiating therapy.